An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.

Abstract

Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML, whereas transplantation remains a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia. Reduced-intensity conditioning has decreased the treatment-related mortality, and advances in the use of alternative donors for transplantation could extend the use of this procedure to an increasing number of patients with improved safety and efficacy. Here we review the current knowledge about allogeneic transplantation for myeloproliferative neoplasms and discuss the most important aspects to be considered when contemplating transplantation for patients with these diseases. Janus kinase 2 inhibitors offer the promise to improve spleen size and performance of patients with myelofibrosis and extend transplantation for patients with more advanced disease.

• Authors: K Adekola, U Popat, S O Ciurea
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 49 Issue 11 Pg. 1352-9 (Nov 2014) ISSN: 1476-5365 [Electronic] England
• PMID: 25089599 (Publication Type: Journal Article, Review)

Chemical References

• Neoplasm Proteins
• Protein Kinase Inhibitors
• JAK2 protein, human
• Janus Kinase 2

Topics

• Allografts
• Hematologic Neoplasms (enzymology, therapy)
• Hematopoietic Stem Cell Transplantation
• Humans
• Janus Kinase 2 (antagonists & inhibitors)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (enzymology, therapy)
• Neoplasm Proteins (antagonists & inhibitors, metabolism)
• Primary Myelofibrosis (enzymology, therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Transplantation Conditioning (methods)